Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Illerhaus

Showing results (41-50 of 80) with videos related to

Pageof 8
Sort By:
Onkologie|February 5, 2005
Meeting report: primary central nervous system lymphoma: standards of care and future perspectivesUlrich Herrlinger, Agnieszka Korfel, Holger Hebart, et al.
BMC Cancer|April 22, 2016
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix)Elisabeth Schorb, Juergen Finke, Andrés J M Ferreri, et al.
BMC Cancer|September 10, 2022
Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphomaJulia Wendler, Christopher P Fox, Elke Valk, et al.
Haematologica|November 13, 2012
Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group projectJacoline E Bromberg, Jeanette K Doorduijn, Gerald Illerhaus, et al.
British Journal of Haematology|May 27, 2020
Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysisEliza M Lauer, Miguel Waterhouse, Moritz Braig, et al.
Haematologica|December 11, 2025
Rituximab, Dexamethasone, Etoposide, Ifosfamide and Carboplatin (R-DeVIC) in relapsed or refractory central nervous system lymphoma - a retrospective multicentre clinical studyKudret Kama, Hannes Treiber, Alexandra Kutilina, et al.
Frontiers in Immunology|July 26, 2021
Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic LeukemiaAnnika Nelde, Yacine Maringer, Tatjana Bilich, et al.
The Journal of Molecular Diagnostics : JMD|August 4, 2020
Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral BiopsyManuel Montesinos-Rongen, Anna Brunn, Armin Tuchscherer, et al.
BMC Cancer|June 19, 2023
Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)Sylvie Lorenzen, Alix Schwarz, Claudia Pauligk, et al.
Haematologica|January 10, 2013
Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantationElisabeth Schorb, Benjamin Kasenda, Johannes Atta, et al.
Pageof 8

Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Onkologie|February 5, 2005
Meeting report: primary central nervous system lymphoma: standards of care and future perspectivesUlrich Herrlinger, Agnieszka Korfel, Holger Hebart, et al.
BMC Cancer|April 22, 2016
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix)Elisabeth Schorb, Juergen Finke, Andrés J M Ferreri, et al.
BMC Cancer|September 10, 2022
Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphomaJulia Wendler, Christopher P Fox, Elke Valk, et al.
Haematologica|November 13, 2012
Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group projectJacoline E Bromberg, Jeanette K Doorduijn, Gerald Illerhaus, et al.
British Journal of Haematology|May 27, 2020
Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysisEliza M Lauer, Miguel Waterhouse, Moritz Braig, et al.
Haematologica|December 11, 2025
Rituximab, Dexamethasone, Etoposide, Ifosfamide and Carboplatin (R-DeVIC) in relapsed or refractory central nervous system lymphoma - a retrospective multicentre clinical studyKudret Kama, Hannes Treiber, Alexandra Kutilina, et al.
Frontiers in Immunology|July 26, 2021
Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic LeukemiaAnnika Nelde, Yacine Maringer, Tatjana Bilich, et al.
The Journal of Molecular Diagnostics : JMD|August 4, 2020
Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral BiopsyManuel Montesinos-Rongen, Anna Brunn, Armin Tuchscherer, et al.
BMC Cancer|June 19, 2023
Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)Sylvie Lorenzen, Alix Schwarz, Claudia Pauligk, et al.
Haematologica|January 10, 2013
Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantationElisabeth Schorb, Benjamin Kasenda, Johannes Atta, et al.
Pageof 8